Nyxoah Announces Preliminary Results for the Second Quarter of 2025
NYXHNyxoah Announces Preliminary Results for the Second Quarter of 2025
August 11, 2025Earnings
Read more →Nyxoah Q1 EPS $(0.63) Misses $(0.50) Estimate, Sales $1.10M Miss $1.64M Estimate
NYXHMay 14, 2025
Read more →Examining the Future: Nyxoah's Earnings Outlook
NYXHMay 13, 2025
Read more →Stifel Maintains Buy on Nyxoah, Lowers Price Target to $14
NYXHApril 21, 2025
Read more →Nyxoah Files Conditional Issuance For Up To 5M Shares At Market Price Under U.S. ATM Program
NYXHApril 16, 2025
Read more →HC Wainwright & Co. Reiterates Buy on Nyxoah, Maintains $15 Price Target
NYXHApril 8, 2025
Read more →Nyxoah Nears FDA Approval For Genio System Following Approvable Letter Confirming PMA Requirements Are Substantially Met
NYXHApril 8, 2025
Read more →HC Wainwright & Co. Maintains Buy on Nyxoah, Lowers Price Target to $15
NYXHMarch 26, 2025
Read more →Nyxoah's Genio System For Obstructive Sleep Apnea Receives Approvable Letter From FDA
NYXHMarch 26, 2025
Read more →Stifel Maintains Buy on Nyxoah, Lowers Price Target to $15
NYXHMarch 14, 2025
Read more →Nyxoah Q4 Sales €1.26M Down From €1.82M YoY, Operating Loss €18.3M Down From €10.8M YoY
NYXHMarch 13, 2025
Read more →Nyxoah Expands Global Footprint With Commercial Launch of Genio In The Middle East
NYXHFebruary 19, 2025
Read more →Nyxoah says, Company fully funded with cash until mid 2026
NYXHNovember 6, 2024
Read more →Nyxoah Q3 EPS $(0.55) Misses $(0.46) Estimate, Sales $1.39M Miss $1.48M Estimate
NYXHNovember 6, 2024
Read more →Cantor Fitzgerald Reiterates Overweight on Nyxoah, Maintains $16 Price Target
NYXHNovember 5, 2024
Read more →Nyxoah Announced The Appointment of John Landry As CFO Effective November 4, 2024
NYXHNovember 4, 2024
Read more →Nyxoah Reduced The Maximum Amount Of 6M Ordinary Shares Available For Issuance Under Its At-the-market Offering
NYXHMay 22, 2024
Read more →Nyxoah Proposes Public Offering Of Ordinary Shares; No Size Or Amount Disclosed
NYXHMay 22, 2024
Read more →